Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by S100B is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. Additionally we are shipping s100b Kits (60) and s100b Proteins (53) and many more products for this protein.
Showing 10 out of 318 products:
Human Polyclonal s100b Primary Antibody for IHC (p), WB - ABIN954658
Sahoo, Tröger, Heinemann, Schönherr: Current inhibition of human EAG1 potassium channels by the Ca2+ binding protein S100B. in FEBS letters 2010
Show all 5 references for ABIN954658
Human Polyclonal s100b Primary Antibody for WB - ABIN658853
Lin, Yang, Wilder, Carrier, Weber: The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. in The Journal of biological chemistry 2010
Show all 4 references for ABIN658853
Cat (Feline) Monoclonal s100b Primary Antibody for EIA, IHC (p) - ABIN114579
Takahashi, Isobe, Ohtsuki, Akagi, Sonobe, Okuyama: Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in human neoplasm and normal tissues. in Virchows Archiv. B, Cell pathology including molecular pathology 1984
Show all 4 references for ABIN114579
Mouse (Murine) Monoclonal s100b Primary Antibody for WB - ABIN659188
van Dieck, Lum, Teufel, Fersht: S100 proteins interact with the N-terminal domain of MDM2. in FEBS letters 2010
Show all 4 references for ABIN659188
Cow (Bovine) Polyclonal s100b Primary Antibody for IHC (fro), IHC (p) - ABIN115345
Kindblom, Lodding, Rosengren, Baudier, Haglid et al.: S-100 protein in melanocytic tumors. An immunohistochemical investigation of benign and malignant melanocytic tumors and metastases of malignant melanoma and a characterization of the antigen in ... in Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology 1984
Show all 2 references for ABIN115345
Human Polyclonal s100b Primary Antibody for IHC (fro), IP - ABIN2712099
Rothoerl, Woertgen, Holzschuh, Metz, Brawanski: S-100 serum levels after minor and major head injury. in The Journal of trauma 1998
Show all 2 references for ABIN2712099
Chicken Polyclonal s100b Primary Antibody for IF, IHC (p) - ABIN181380
Joshi, Lee, Pedersen, Schnitt, Camus, Hughes: The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast. in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1996
Show all 2 references for ABIN181380
Human Monoclonal s100b Primary Antibody for IF, IP - ABIN1108929
Herrera, Turbat-Herrera, Lott: S-100 protein expression by primary and metastatic adenocarcinomas. in American journal of clinical pathology 1988
Show all 2 references for ABIN1108929
Human Polyclonal s100b Primary Antibody for FACS, IHC (p) - ABIN651265
Davila, Froeling, Tan, Bonnard, Boland, Snippe, Hibberd, Seielstad: New genetic associations detected in a host response study to hepatitis B vaccine. in Genes and immunity 2010
Human Polyclonal s100b Primary Antibody for IF (p), IHC (p) - ABIN676703
Zhang, Li, Lu, Liu et al.: Cerebral potential biomarkers discovery and metabolic pathways analysis of ?-synucleinopathies and the dual effects of Acanthopanax senticosus Harms on central nervous system through metabolomics ... in Journal of ethnopharmacology 2015
The results of this study showed that S100B affects behavioral despair in female mice through functional interaction with the 5-HT7 (show HTR7 Antibodies) receptor.
Data show that S100B has direct effects on macrophages, enhancing particularly CCL22 (show CCL22 Antibodies) and IL-1beta (show IL1B Antibodies) expression and modulates the inflammatory response in uveoretinitis and this is likely to be, at least in part, via a direct effect on macrophages.
Data show that high glucose increased protein-protein interaction between Steap4 (show STEAP4 Antibodies) and S100B in mesangial (MES13) cells.
S100A1 (show S100A1 Antibodies)-KO exhibited increased right ventricular (RV) weight and elevated RV pressure in the absence of altered left ventricular filling pressures, increase in wall thickness of muscularized pulmonary arteries and a reduction in microvascular perfusion.
high glucoseinduced profibrotic genes (TGFbeta (show TGFB1 Antibodies), type IV collagen (show COL4 Antibodies) and fibronectin (show FN1 Antibodies)) and cell hypertrophyrelated p21WAF1 are dependent on S100B.
S100A1 (show S100A1 Antibodies) and S100B are dispensable for endochondral ossification during skeletal development.
S100A1 (show S100A1 Antibodies) ablationalso reduced plaque associated and increased non-plaque associated PO4-Akt (show AKT1 Antibodies) and PO4-GSK3beta (show GSK3b Antibodies) staining.
Patients with acute myocardial infarction (MI) showed significantly increased S100A1 (show S100A1 Antibodies) serum levels. Experimental MI in mice induced comparable S100A1 (show S100A1 Antibodies) release. S100A1 (show S100A1 Antibodies) signaling in cardiac fibroblasts occurs through endosomal TLR4 (show TLR4 Antibodies)/MyD88 (show MYD88 Antibodies).
Data suggest up-regulation of S100b/RAGE (show AGER Antibodies) (advanced glycosylation end-product receptor) signaling plays role in inflammatory interaction between adipocytes/macrophages; adipocyte secretion of S100b is up-regulated by Tnf (tumor necrosis factor-alpha (show TNF Antibodies)).
hypoxia-induced MiR (show MLXIP Antibodies)-138 is an essential mediator of EC dysfunction via its ability to target the 3'UTR (show UTS2R Antibodies) of S100A1 (show S100A1 Antibodies).
Serum S100B protein levels increased after general anaesthesia. The values of S100Bp (median 164.0 ng/L) were significantly higher than the values of S100Bb (median 94.5 ng/L). The median of the difference between S100Bp and S100Bb was 58.0 ng/L. There were statistically significant differences between S100Bb and S100Bp.
Although an elevation in S100B was not observed in this (second) ascent during re-exposure to the hypobaric hypoxia of high altitude for either the non-treated (acclimatised) or the dexamethasone treated (acclimatised and dexamethasone) groups, the hypothesis that S100B would reduce following acclimatisation could not be statistically confirmed in our study given the wide confidence intervals and small sample size
Serum S100B is a useful quantitative biomarker in routine follow-up of high-risk melanoma patients.
There was no association found between serum and CSF (show CSF2 Antibodies) S100B with radiographic vasospasm or DIND. S100B is a potential prognostic marker for aSAH (show ASAH1 Antibodies) outcome
Fetuses of active smoker mothers had lower cord blood S100B levels compared to fetuses of non-smoker mothers.
This study inquires into the physiological concentrations of NSE (show ENO2 Antibodies) and S100B proteins in CSF (show CSF2 Antibodies), carried out on a sufficiently large group of 601 patients.
Studied circulating S100B and adiponectin (show ADIPOQ Antibodies) in children who underwent open heart surgery. S100B showed a significant increase from hospital admission up to 24 h after procedure.
Concentrations of serum S100B protein in brain-dead organ donors are extremely high and may support the diagnosis of brain death.
long-term exposure to high blood glucose concentrations leads to an increase in total oxidant in patients with diabetic ketoacidosis ( and that the neurotransmitter changes that develop in response to this exposure lead to an increase in S100B levels
plasma biomarkers S100-B and copeptin (show AVP Antibodies) did not improve prediction of poor outcome following seizure
As CSF (show CSF2 Antibodies)-S100B levels in calves with neurologic diseases widely differed, the utility of CSF (show CSF2 Antibodies)-S100B as a diagnostic marker for neurologic diseases in cattle remains inconclusive.
S100B might participate in the pathophysiology of brain inflammatory disorders via RAGE (show AGER Antibodies)-dependent regulation of several inflammation-related events including activation and migration of microglia
X-ray crystallography was used here to characterize an interaction between Ca(2 (show CA2 Antibodies))(+)-S100B and TRTK-12, a target that binds to the p53 (show TP53 Antibodies)-binding site on S100B.
Intracellular S100B might modulate myoblast differentiation by interfering with MyoD (show MYOD1 Antibodies) expression in an NF-kappaB (show NFKB1 Antibodies)-dependent manner.
S100b activates guanylate cyclase in a calcium-dependent manner [review]
Structural studies in combination with biochemical data are used to develop a model for calcium-induced activation of human nuclear serine/threonine kinase (NDR (show STK38 Antibodies)) kinase by S100B.
S100B shows a sufficient thermostability to resist pasteurization but not spry-drying in milk formulas for preterm and term infants.
Structures of pentamidine (Pnt (show ETS2 Antibodies)) bound to Ca(2 (show CA2 Antibodies)+)-loaded and Zn(2+),Ca(2 (show CA2 Antibodies)+)-loaded S100B were determined by X-ray crystallography at 2.15 A (R(free)=0.266) and 1.85 A (R(free)=0.243) resolution, respectively.
The time course of S100B serum values following spinal cord decompression correlates with outcome; the initial degree of paresis is not a prognostic factor to predict outcome.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21\; however, this gene is located at 21q22.3. This protein may function in Neurite extension, proliferation of melanoma cells, stimulation of Ca2+ fluxes, inhibition of PKC-mediated phosphorylation, astrocytosis and axonal proliferation, and inhibition of microtubule assembly. Chromosomal rearrangements and altered expression of this gene have been implicated in several neurological, neoplastic, and other types of diseases, including Alzheimer's disease, Down's syndrome, epilepsy, amyotrophic lateral sclerosis, melanoma, and type I diabetes.
S-100 protein alpha chain
, S-100 protein subunit alpha
, S100 calcium-binding protein A1
, protein S100-A1
, S-100 calcium-binding protein, beta chain
, S-100 protein subunit beta
, S100 calcium-binding protein, beta (neural)
, protein S100-B
, S-100 protein beta chain
, S100 calcium-binding protein B
, S100 protein, beta polypeptide
, S-100 calcium-binding protein beta subunit
, S100 calcium-binding protein beta (neural)
, S100 protein, beta polypeptide, neural
, S100 calcium binding protein, beta (neural)
, S100 calcium-binding protein, beta